

Neisseria meningitidis (6151): sc-58175

BACKGROUND

Neisseria meningitidis is a Gram-negative bacteria responsible for the illness bacterial meningitis. Residing within the nasopharyngeal tract of humans, *Neisseria meningitidis* does not affect any other animals. Responsible for the only form of meningitis to cause epidemics, different strains of *Neisseria meningitidis* are characterized by a polysaccharide expressed on its capsule. This capsular polysaccharide antagonizes a T-independent immune response, further eluding long term immunity by conferring neither memory cell formation nor antibody affinity maturation. Though bacterial meningitis begins as a "sick all over syndrome", it can quickly evolve from fever, headache and neck stiffness into coma and death. With mortality resulting in approximately 10% of all cases, suspicion of meningitis warrants a medical emergency necessitating immediate medical assessment. Persons most susceptible to the infection are often immunocompromised, immunosuppressed or suffering from head trauma. Others acquire infection through close contact with a primary carrier.

REFERENCES

1. Fowler, M.I., Yin, K.Y., Humphries, H.E., Heckels, J.E. and Christodoulides, M. 2006. Challenge with *Neisseria lactamica* and with *Neisseria meningitidis*. *Infect. Immun.* 74: 6467-6478.
2. Chanteau, S., Dartevelle, S., Mahamane, A.E., Djibo, S., Boisier, P. and Nato, F. 2006. New rapid diagnostic tests for *Neisseria meningitidis* serogroups A, W135, C and Y. *PLoS Med.* 3: e337.
3. Clarke, S.C. 2006. Detection of *Neisseria meningitidis*, *Streptococcus pneumoniae* and *Haemophilus influenzae* in blood and cerebrospinal fluid using fluorescence-based PCR. *Methods Mol. Biol.* 345: 69-77.
4. Borrow, R., Carlone, G.M., Rosenstein, N., Blake, M., Feavers, I., Martin, D., Zollinger, W., Robbins, J., Aaberge, I., Granoff, D.M., Miller, E., Plikaytis, B., van Alphen, L., Poolman, J., Rappuoli, R., Danzig, L., et al. 2006. *Neisseria meningitidis* group B correlates of protection and assay standardization—international meeting report Emory University, Atlanta, Georgia, United States, 16-17 March 2005. *Vaccine* 24: 5093-5107.
5. Gottfredsson, M., Diggle, M.A., Lawrie, D.I., Erlensdóttir, H., Hardardóttir, H., Kristinsson, K.G. and Clarke, S. 2006. *Neisseria meningitidis* sequence type and risk for death, Iceland. *Emerg. Infect. Dis.* 12: 1066-1073.
6. Mesa, C., de León, J., Rigley, K. and Fernández, L.E. 2006. Very small size adjuvant for dendritic cell activation. *Vaccine* 24: S2-42-43.
7. Balboa, J.A., Cuello, M., Cabrera, O., del Campo, J., Lastre, M., Gil, D., Taboada, C., Fariñas, M., Hernández, M. and Perez, O. 2006. Adjuvant properties of lipopolysaccharide from *Neisseria meningitidis* serogroup B detoxified and conjugated with tetanus toxoid. *Vaccine* 24: S2-63-64.
8. Scarselli, M., Serruto, D., Montanari, P., Capecchi, B., Adu-Bobie, J., Veggi, D., Rappuoli, R., Pizza, M. and Aricò, B. 2006. *Neisseria meningitidis* NhhA is a multifunctional trimeric autotransporter adhesin. *Mol. Microbiol.* 61: 631-644.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

SOURCE

Neisseria meningitidis (6151) is a mouse monoclonal antibody raised against *Neisseria meningitidis* LPS serotype L10, serogroup A.

PRODUCT

Each vial contains 100 µg IgG₃ in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

APPLICATIONS

Neisseria meningitidis (6151) is recommended for detection of LPS serotype L10, serogroup A of *Neisseria meningitidis* origin by immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500).

STORAGE

Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.